Carla Cases

Dr. Carla Cases

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMeritxell Mollà
Meritxell Mollà
JFJulen Fernandez-Plana
Julen Fernandez-Plana
SASantiago Albiol
Santiago Albiol
CFConstantino Fondevila
Constantino Fondevila
IVIvan Vollmer
Ivan Vollmer
EPEstela Pineda
Estela Pineda
The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians’ factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments.

22 November 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
ABAlbert Biete
Albert Biete
IVIzaskun Valduvieco
Izaskun Valduvieco
CCCarla Cases
Carla Cases
JFJenaro Fernández-Valencia
Jenaro Fernández-Valencia
LMLuis Alfonso Moreno
Luis Alfonso Moreno
MMMeritxell Mollà
Meritxell Mollà

24 November 2021 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
DMDiego Muñoz-Guglielmetti
Diego Muñoz-Guglielmetti
DSDavid Sanchez-Lorente
David Sanchez-Lorente
RRRoxana Reyes
Roxana Reyes
DMDaniel Martínez
Daniel Martínez
CLCarmen Lucena
Carmen Lucena
FCFrancesc Casas
Francesc Casas
Neoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Study of Lung Cancer (IASLC) published recommendations for the pathological response (PHR) of NSCLC resection specimens after NT. To contribute to the IASLC recommendations showing our results of PHR to NT Ch vs NT chemoradiotherapy (ChRT). We analyzed 67 consecutive patients with resectable stage III NSCLC with positive mediastinal nodes treated with surgery after NT Ch or NT ChRT between 2013 and 2020. After NT, all patients were evaluated for radiological response (RR) according to Response Evaluation Criteria in Solid Tumours criteria and evaluated for surgery by a specialized group of thoracic surgeons. All histological samples were examined by the same two pathologists. PHR was evaluated by the percentage of viable cells in the tumor and the resected lymph nodes. Forty patients underwent NT ChRT and 27 NT Ch. Fifty-six (83.6%) patients underwent surgery (35 ChRT and 21 Ch). The median time from ChRT to surgery was 6 wk (3-19) and 8 wk (3-21) for Ch patients. We observed significant differences in RR, with disease progression in 2.5% and 14.8% of patients with ChRT and Ch, respectively, and partial response in 62.5% ChRT vs 29.6% Ch (P = 0.025). In PHR we observed ≤ 10% viable cells in the tumor in 19 (54.4%) and 2 cases (9.5%), and in the resected lymph nodes (RLN) 30 (85.7%) and 7 (33.3%) in ChRT and Ch, respectively (P = 0.001). Downstaging was greater in the ChRT compared to the Ch group (80% vs 33.3%; P = 0.002). In the univariate analysis, NT ChRT had a significant impact on partial RR [odds ratio (OR) 12.5; 95% confidence interval (CI): 1.21 - 128.61; P = 0.034], a decreased risk of persistence of cancer cells in the tumor and RLN and an 87.5% increased probability for achieving downstaging (OR 8; 95%CI: 2.34-27.32; P = 0.001). We found significant benefits in RR and PHR by adding RT to Ch as NT. A longer follow-up is necessary to assess the impact on clinical outcomes.

21 February 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CCCarla Cases
Carla Cases
MBMariana Benegas
Mariana Benegas
MSMarcelo Sánchez
Marcelo Sánchez
IVIvan Vollmer
Ivan Vollmer
FCFrancesc Casas
Francesc Casas
MMMeritxell Mollà
Meritxell Mollà

24 January 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CCCarla Cases
Carla Cases
GOGabriela Oses
Gabriela Oses
AHAntonio Herreros
Antonio Herreros
JTJordi Tarrats-Rosell
Jordi Tarrats-Rosell
SMSara Moreno
Sara Moreno
MMMeritxell Mollà
Meritxell Mollà

29 November 2024 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
CCCarla Cases
Carla Cases
MMMeritxell Mollà
Meritxell Mollà
MSMarcelo Sánchez
Marcelo Sánchez
MBMariana Benegas
Mariana Benegas
MBMarc Ballestero
Marc Ballestero
CGCarles Gomà
Carles Gomà
Introduction: Treatment of neoplasic lung nodules with ground glass opacities (GGO) faces two primary challenges. First, the standard practice of treating GGOs as solid nodules, which effectively controls the tumor locally, but might increase associated toxicities. The second is the potential for dose calculation errors related to increased heterogeneity. This study addresses the optimization of a dose de-escalation regime for stereotactic ablative radiotherapy (SABR) for GGO lesions. Materials and Methods: We used the CT scans of 35 patients (40 lesions) with some degree of GGO component treated at our institution between 2017 and 2021. We first assessed the dose calculation accuracy as a function of the GGO component of the lesion. We then analysed the advantages of a dose de-escalation regime in terms of lung dose reduction (Dmean, V20Gy and V300GyBED3) and plan robustness. Results: We found a positive correlation between the presence of GGO and the dose calculation errors in a phantom scenario. These differences are reduced for patient data and in the presence of breathing motion. When using a de-escalation regime, significant reductions were achieved in mean lung dose, V20Gy and V300GyBED3. This study also revealed that lower doses in GGO areas lead to more stable fluence patterns, increasing treatment robustness. Conclusions: The study lays the foundation for an eventual use of dose de-escalation in SABR for treating lung lesions with GGO, potentially leading to equivalent local control while reducing associated toxicities. These findings lay the groundwork for future clinical trials.